A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy

Qi Xue, Jianjian Peng, Wenkui Dai, Qingsong Wu, Jinbiao Jiao, Yudi Hu, Wanxing Sha, Yang Yang, Wenhao Yu, Siyang Liu, Ting Xu, Jie LiRSC 2025 · DOI

Abstract

HER2 is overexpressed in approximately 15-20% of cancers and is associated with aggressive disease progression. We developed JSKN003, a bispecific HER2-targeted antibody-drug conjugate (ADC), through site-specific conjugation technology based on N-glycosylation engineering. JSKN003 maintains a biantennary glycan structure and exhibits superior structural homogeneity, optimized hydrophilicity, and reduced aggregation compared to conventional thiol-maleimide chemistry. In preclinical models JSKN003 demonstrated potent antitumor efficacy, inducing tumor regression in multiple HER2-expressing tumors, such as NCI-N87, BxPC-3, and PDX tumor models. Mechanistically, JSKN003 binds specifically to HER2, undergoes efficient internalization, and traffics to the lysosome, where the payload DXd is released, leading to DNA damage and apoptosis. JSKN003 retained its cytotoxic activity against trastuzumab-resistant cells, attributed to efficient payload delivery and blockade of downstream HER2 signaling pathways, demonstrating the potential to overcome clinical trastuzumab resistance. The safety profile of JSKN003 was evaluated in cynomolgus monkeys and was found to be acceptable, with no severe toxicities observed at therapeutic doses. JSKN003 demonstrated excellent antitumor activity and a favorable safety profile in clinical trials, highlighting its potential as a promising therapeutic option for patients with HER2-positive tumors. These findings suggest that JSKN003 could be a valuable therapeutic strategy with excellent efficacy and safety for HER2-expressing tumors in the clinical setting.

Introduction

Antibody-drug conjugates (ADCs) are designed to deliver cytotoxic payloads directly to cancer cells, minimizing systemic toxicity. However, current clinical standards for HER2-positive cancers, such as DS-8201a (Enhertu), face challenges related to product heterogeneity and stability. Most conventional ADCs utilize thiol-maleimide chemistry, which attaches payloads to cysteine residues, often resulting in a mixture of molecules with varying drug-to-antibody ratios (DAR). This heterogeneity can lead to physical instability and premature payload release, contributing to off-target toxicities like Interstitial Lung Disease (ILD). Furthermore, many tumors eventually develop resistance to trastuzumab-based therapies. JSKN003 was developed to address these hurdles through a combination of biparatopic targeting and site-specific glycan engineering.

Methodology

JSKN003 was constructed using a multi-step chemoenzymatic approach to ensure high homogeneity and stability:

  • Biparatopic Antibody Design: The ADC utilizes KN026, a bispecific antibody that targets two non-overlapping epitopes on the HER2 receptor (domains II and IV). This dual-binding approach enhances receptor internalization and helps bypass resistance mechanisms associated with monospecific antibodies.
  • Site-Specific Glycan Engineering: Rather than targeting amino acid residues, the researchers targeted the N-glycans on the antibody's Fc region. Using a mutant GalT1 enzyme, azide groups were installed onto these sugar chains.
  • Click Chemistry Conjugation: The payload, DXd (a topoisomerase I inhibitor), was attached via Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC). This "click chemistry" method resulted in a highly homogeneous ADC with a DAR of approximately 3.6.
  • Analytical Characterization: The physical properties and purity of JSKN003 were validated using LC-MS, Hydrophobic Interaction Chromatography (HIC), and Size-Exclusion Chromatography (SEC).

Results and Discussion

Superior Stability and Physical Properties

By attaching the payload to glycans rather than the protein backbone, JSKN003 exhibits increased hydrophilicity. This prevents the aggregation typically seen in high-potency ADCs. In serum stability tests, JSKN003 remained almost entirely intact over 96 hours, whereas the clinical comparator DS-8201a lost nearly 50% of its payload. This suggests that JSKN003 is significantly less likely to release its toxic payload into healthy tissue during circulation.

Potent Antitumor Activity and Resistance Bypass

JSKN003 demonstrated robust efficacy across various preclinical models, including HER2-high (NCI-N87) and HER2-low (BxPC-3) cell lines. In NCI-N87 xenografts, a dose of 2 mg/kg achieved 85% tumor growth inhibition (TGI). Crucially, JSKN003 maintained strong cytotoxic activity against trastuzumab-resistant cells, a setting where the parent antibody KN026 failed. The membrane-permeable nature of the released DXd also enables a "bystander effect," allowing the drug to kill neighboring cancer cells with low HER2 expression within heterogeneous tumors.

Safety and Toxicology

In safety evaluations using cynomolgus monkeys, the highest non-severely toxic dose (HNSTD) was determined to be 30 mg/kg. Unlike many conventional ADCs, JSKN003 did not induce severe hematological or pulmonary toxicities at therapeutic dose levels, indicating a favorable safety profile for clinical transition.

Conclusion and Future Directions

JSKN003 represents a next-generation ADC strategy that improves upon traditional conjugation methods. While its DAR (~3.6) is lower than that of DS-8201a (~8), its superior stability and biparatopic binding appear to compensate for the lower drug load, particularly in resistant and HER2-low models. JSKN003 is currently undergoing Phase I/II/III clinical trials to further evaluate its efficacy and the incidence of rare side effects in human cohorts. Future research may also explore combining JSKN003 with immune checkpoint inhibitors to leverage its ability to induce immunogenic cell death.

Summary updated

Abstract

HER2 is overexpressed in approximately 15-20% of cancers and is associated with aggressive disease progression. We developed JSKN003, a bispecific HER2-targeted antibody-drug conjugate (ADC), through site-specific conjugation technology based on <i>N</i>-glycosylation engineering. JSKN003 maintains a biantennary glycan structure and exhibits superior structural homogeneity, optimized hydrophilicity, and reduced aggregation compared to conventional thiol-maleimide chemistry. In preclinical models JSKN003 demonstrated potent antitumor efficacy, inducing tumor regression in multiple HER2-expressing tumors, such as NCI-N87, BxPC-3, and PDX tumor models. Mechanistically, JSKN003 binds specifically to HER2, undergoes efficient internalization, and traffics to the lysosome, where the payload DXd is released, leading to DNA damage and apoptosis. JSKN003 retained its cytotoxic activity against trastuzumab-resistant cells, attributed to efficient payload delivery and blockade of downstream HER2 signaling pathways, demonstrating the potential to overcome clinical trastuzumab resistance. The safety profile of JSKN003 was evaluated in cynomolgus monkeys and was found to be acceptable, with no severe toxicities observed at therapeutic doses. JSKN003 demonstrated excellent antitumor activity and a favorable safety profile in clinical trials, highlighting its potential as a promising therapeutic option for patients with HER2-positive tumors. These findings suggest that JSKN003 could be a valuable therapeutic strategy with excellent efficacy and safety for HER2-expressing tumors in the clinical setting.
BibTeX
@inproceedings{xue2025biparatopic,
  author = {Qi Xue and Jianjian Peng and Wenkui Dai and Qingsong Wu and Jinbiao Jiao and Yudi Hu and Wanxing Sha and Yang Yang and Wenhao Yu and Siyang Liu and Ting Xu and Jie Li},
  title = {{A biparatopic HER2-targeting ADC constructed <i>via</i> site-specific glycan conjugation exhibits superior stability, safety, and efficacy}},
  booktitle = {RSC},
  year = {2025},
  doi = {10.1039/d5cb00096c},
}
Figure